160 related articles for article (PubMed ID: 20360589)
1. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.
Xamplas RC; Itokazu GS; Glowacki RC; Grasso AE; Caquelin C; Schwartz DN
Am J Health Syst Pharm; 2010 Apr; 67(8):622-8. PubMed ID: 20360589
[TBL] [Abstract][Full Text] [Related]
2. Development and implementation of a piperacillin-tazobactam extended infusion guideline.
Heinrich LS; Tokumaru S; Clark NM; Garofalo J; Paek JL; Grim SA
J Pharm Pract; 2011 Dec; 24(6):571-6. PubMed ID: 21676847
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
4. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
Schmees PM; Bergman SJ; Strader BD; Metzke ME; Pointer S; Valenti KM
Am J Health Syst Pharm; 2016 Jun; 73(11 Suppl 3):S100-5. PubMed ID: 27208142
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
8. Effect of adding piperacillin-tazobactam to automated dispensing cabinets on promptness of first-dose antibiotics in hospitalized patients.
Lo A; Zhu JN; Richman M; Joo J; Chan P
Am J Health Syst Pharm; 2014 Oct; 71(19):1663-7. PubMed ID: 25225451
[TBL] [Abstract][Full Text] [Related]
9. Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam.
Lam WJ; Bhowmick T; Gross A; Vanschooneveld TC; Weinstein MP
Ann Pharmacother; 2013 Jun; 47(6):886-91. PubMed ID: 23715072
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
11. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
Florea NR; Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Am J Health Syst Pharm; 2003 Nov; 60(22):2321-7. PubMed ID: 14652981
[TBL] [Abstract][Full Text] [Related]
13. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
D'Agostino C; Rhodes NJ; Skoglund E; Roberts JA; Scheetz MH
J Infect Chemother; 2015 Oct; 21(10):742-6. PubMed ID: 26143049
[TBL] [Abstract][Full Text] [Related]
14. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
16. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
[TBL] [Abstract][Full Text] [Related]
17. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
19. System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective.
Nichols KR; Knoderer CA; Cox EG; Kays MB
Clin Ther; 2012 Jun; 34(6):1459-65. PubMed ID: 22657253
[TBL] [Abstract][Full Text] [Related]
20. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
